Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Introduction - ten commandments
3. IDU
4. TFT
5. Methisazone
6. Amantadine
7. Ribavirin
8. Ara-A
9. HIV
10. Replicative cycle of HIV
11. Suramin
12. Zidovudine
13. Emtricitabine
14. TDF
15. Drug interrelations and combination
16. Truvada
17. Atripla
18. Complera
19. Quad (stribild)
20. GS-7340
21. Quad (planned)
22. Another planned quad
23. Cobicistat & Ritonavir
24. HCV
25. HCV genome and potential targets
26. Available HCV drugs
27. Telaprevir
28. Boceprevir
29. Asunaprevir
30. GS-9256
31. GS-9451
32. Danoprevir
33. Vaniprevir
34. Narlaprevir
35. Simeprevir
36. Drugs which target NS5A
37. Daclatasvir
38. Drugs that target NS5B (nucleoside)
39. Sofosbuvir
40. Mericitabine
41. Drugs that target NS5B (non-nucleoside)
42. VX-222
43. BI 201335
44. Tegobuvir
45. Setrobuvir
46. Filibuvir
47. VCH-916 & VCH-759
48. Drugs that target cellular enzymes
49. Alisporivir
50. The principle for the future treatment of HCV
51. Phase II DAA-based combination clinical trials
52. HSV
53. Acyclovir
54. Valaciclovir
55. Penciclovir & Famciclovir
56. HSV DNA synthesis
57. AIC316
58. VZV
59. BVDU
60. Degradation of BVDU to BVU
61. Cf 1743 & FV-100
62. ASP2151
63. HCMV
64. Ganciclovir & Valganciclovir
65. Phosphonoformic acid: Foscarnet
66. HPMPC
67. Maribavir
68. Letermovir
69. Poxviruses
70. Post-exposure treatments for monkeypox virus
71. HDP-cidofovir
72. ST-246
73. HBV
74. Anti-HBV agents
75. Lamivudine
76. Adefovir dipivoxil
77. Entecavir
78. Telbivudine
79. Viread
80. CHB virologic response
81. Influenza virus
82. Antiviral influenza replication inhibition
83. Zanamivir
84. Oseltamivir (tamiflu)
85. Tamiflu packaging
86. RWJ-270201: Peramivir
87. Laninamivir octanoate
88. Favipiravir
89. Favipiravir mechanism
90. Enveloped viruses
91. Neplanocin A
92. dUY11
93. LJ-001
94. FGI-106
95. Picornaviruses
96. Pleconaril
97. Pirodavir
98. Rupintrivir
99. TBZE-029
100. City hall
101. Rega institute building
102. Henri Joseph Rega
103. Mentor
104. Seed of wisdom

Topics Covered

• Chemotherapy of virus infections, AIDS, and malignant diseases
• Molecular mechanism of action & enzyme targets of antiviral and antitumor agents
• Nucleoside and nucleotide analogues
• Reverse transcriptase inhibitors
• Virus adsorption, fusion and uncoating inhibitors

Links

Series:

• Antivirals
• Small Molecule Drug Discovery

Categories:

• Biochemistry
• Clinical Practice
• Microbiology
• Pharmaceutical Sciences

Therapeutic Areas:

• Infectious Diseases

Talk Citation

De Clercq, E. (2013, September 23). Current trends in antiviral drug development [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 27, 2024, from https://doi.org/10.69645/LHVX4583.
Export Citation (RIS)

Publication History

• Published on September 23, 2013

Financial Disclosures

• Prof. Dr. Erik De Clercq has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.